Drug profile · INN
fostamatinib
TAVLESSE
fostamatinib (TAVLESSE) is a tyrosine-protein kinase syk inhibitor.
EMA: approved Blood and blood forming organs (B02) B02BX
Patents linked 0
Pipeline programs 17
News articles 0
Drug details — fostamatinib
- Class
- Blood and blood forming organs (B02)
- Route
- —
- Patents
- 0
- Programs
- 17
- Data quality
- 0.83
Quick answer
fostamatinib (TAVLESSE) is a tyrosine-protein kinase syk inhibitor.
Key facts
INN fostamatinib
Brand TAVLESSE
Mechanism Tyrosine-protein kinase SYK inhibitor
Target Tyrosine-protein kinase SYK
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BX
Mechanism of action
Tyrosine-protein kinase SYK inhibitor
Primary target: Tyrosine-protein kinase SYK
Approval history
| Authority | Status | Date |
|---|---|---|
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is fostamatinib?
fostamatinib (TAVLESSE) is a tyrosine-protein kinase syk inhibitor.
What is the brand name for fostamatinib?
TAVLESSE is a marketed brand name for fostamatinib. Check FDA Drugs@FDA for the current US label holder and prescribing information.